The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Pharmacology · Pharmacokinetics · continued

Coming back to: Washout: how long is long enough, and for what purpose posts 61–90

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

VK
v.klausenTL3Regular5 Mar 2026#61

Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.

19 likes 5mo
SS
s.solbergTL26 Mar 2026#62

Small methodological point on Washout: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

0 likes 5mo
ID
integrator_draftTL3Regular7 Mar 2026#63

Where I would push back on the Washout consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.

2 likes 5mo
YR
y.ramosTL28 Mar 2026#64
VM
v.milanoviTL3Regular9 Mar 2026#65

Taking post #62 at face value and following it one step further.

A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.

That is the honest state of it as of this week.

13 likes 5mo
PF
p.friskTL210 Mar 2026#66

Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number.

I checked the source rather than the summary, and they differ.

27 likes 5mo
AS
a.stephanopoulosTL3Regular11 Mar 2026#67

Trying to state the Washout position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.

0 likes 5mo
FP
f.petrovTL212 Mar 2026 · edited#68
a.mwangi, post #14: Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number. One case, stated as one case. Go to post

Washout sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.

4 likes in reply to #14 5mo
JS
j.sorensenTL213 Mar 2026#69

Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.

That distinction has done more work for me than anything else in this category.

8 likes 5mo
JC
j.castellanosTL214 Mar 2026#70

Post #68 put the caveat in the right place and I want to underline it.

Distinguishing three things in the Washout discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.

20 likes 4mo
VK
v.kirchnerTL215 Mar 2026#71
taper_table, post #29: Post #26 is right about the mechanism and I think understates the practical bit. Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available. Go to post

A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.

12 likes in reply to #29 4mo
VS
v.szaboTL3Analytical chemist16 Mar 2026#72
a.mwangi, post #14: Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number. One case, stated as one case. Go to post

Washout: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.

4 likes in reply to #14 4mo
CV
c.vasquezTL216 Mar 2026 · edited#73

Coming back to post #71, because the follow-up matters more than the original answer.

The claim about Washout upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".

0 likes 4mo
AF
a.finnegan_rdTL2Dietitian17 Mar 2026#74

Post #71 is right about the mechanism and I think understates the practical bit.

Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.

I would treat the number as indicative rather than as a measurement.

25 likes 4mo
PO
p.ostergaardTL218 Mar 2026#75

Practical experience of Washout, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.

18 likes 4mo
CL
customs_ledgerTL3Regular19 Mar 2026#76
g.ekstrom, post #22: I had read the opposite somewhere and cannot now find where, which tells me something. Go to post

Taking post #75 at face value and following it one step further.

Two sentences on Washout and then I will stop, because the rest is speculation and the thread is better without mine.

What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.

7 likes in reply to #22 4mo
SG
s.girardTL220 Mar 2026#77

Good question, well framed, and I would like to see it answered properly.

0 likes 4mo
LE
logbook_erinTL3Regular21 Mar 2026#78

Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.

0 likes 4mo
KS
k.salinasTL222 Mar 2026#79

Post #75 put the caveat in the right place and I want to underline it.

Washout after stopping takes roughly the same four to five half-lives as reaching steady state. A month after the last dose is not the same as none.

I have said this before in a thread nobody could find, so it is worth repeating.

4 likes 4mo
ME
me.eriksenTL223 Mar 2026#80
m.restrepo, post #32: The arithmetic in post #31 is right; the assumption feeding it is the part to check. Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability. I looked this up rather than remembered it, which is the right order. Go to post

Filing a mild objection to the consensus on Washout. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.

0 likes in reply to #32 4mo
IO
i.oseiTL224 Mar 2026#81

Offering a way to settle Washout rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.

10 likes 4mo
O
OkaforTL3Regular25 Mar 2026#82

Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.

22 likes 4mo
ID
il.dumitruTL226 Mar 2026#83

Adding the measurement that post #80 says would settle it.

Where the Washout discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.

0 likes 4mo
GH
g.haalandTL3Regular27 Mar 2026 · edited#84
b.vestergaard, post #12: Picking up post #9: that is the part I would want checked first. The question underneath Washout is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting… Go to post

Thank you — that answers what I came here to find out.

1 like in reply to #12 4mo
NZ
n.zielinskiTL227 Mar 2026#85

A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.

15 likes 4mo
M
MJayawardenaTL3Regular28 Mar 2026#86

Coming back to post #82, because the follow-up matters more than the original answer.

Reframing Washout slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.

29 likes 4mo
DN
d.nilsenTL229 Mar 2026#87
crossover_entry, post #3: Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability. Go to post

The bit of Washout that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.

0 likes in reply to #3 4mo
O
OTeixeiraTL3Regular30 Mar 2026 · edited#88
g.ekstrom, post #22: I had read the opposite somewhere and cannot now find where, which tells me something. Go to post

Washout after stopping takes roughly the same four to five half-lives as reaching steady state. A month after the last dose is not the same as none.

3 likes in reply to #22 4mo
MY
m.yilmazTL231 Mar 2026#89

Thank you for the correction. I would rather find out here than later.

21 likes 4mo
GI
g.ibarraTL21 Apr 2026#90

Washout came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.

0 likes 4mo